Valuation : Endonovo Therapeutics Inc

Market Cap 2.77M 2.39M 2.24M 2.05M 3.84M 264M 3.87M 26.57M 10.34M 134M 10.41M 10.19M 443M P/E 2021
-0.3x
P/E 2022 -0.14x
Enterprise Value 9.93M 8.55M 8.02M 7.33M 13.76M 944M 13.86M 95.09M 37M 479M 37.27M 36.46M 1.59B EV / Sales 2021
112,421,804x
EV / Sales 2022 78,689,579x
Free-Float
100%
Yield 2021 *
-
Yield 2022 -
Manager TitleAgeSince
Chief Executive Officer 61 2012-02-29
Investor Relations Contact - 2014-04-30
Corporate Officer/Principal 77 2022-11-29
Director TitleAgeSince
Chairman 61 2012-02-29
Change 5-day change 1-year change 3-year change Capi.($)
-1.66%-4.96%+49.84%+88.43% 69.54B
-2.19%+1.32%+44.54%+88.38% 64.97B
-3.57%-4.24%+47.11%+5.60% 26.51B
+2.83%-1.18%-15.68%+459.68% 25.89B
-0.46%-10.00%+0.91%-16.03% 25.64B
-9.71%-0.36%+245.87%+377.68% 20.22B
-1.58%+0.47%+29.35%-19.62% 19.98B
-3.36%-7.58%+9.47%+535.81% 15.69B
+0.34%+0.57%+47.55%+145.02% 13.49B
Average -2.05%-3.70%+50.99%+184.99% 31.33B
Weighted average by Cap. -1.95%-3.50%+48.15%+145.90%

Financials

2021 2022
Net sales 0.07 0.06 0.06 0.05 0.1 6.96 0.1 0.7 0.27 3.53 0.27 0.27 11.68 0.14 0.12 0.11 0.1 0.19 12.88 0.19 1.3 0.5 6.53 0.51 0.5 21.62
Net income -3.1M -2.67M -2.51M -2.29M -4.3M -295M -4.34M -29.74M -11.57M -150M -11.66M -11.4M -496M -18.47M -15.91M -14.94M -13.63M -25.61M -1.76B -25.8M -177M -68.86M -891M -69.37M -67.86M -2.95B
Net Debt 7.1M 6.11M 5.74M 5.24M 9.84M 675M 9.91M 67.97M 26.45M 342M 26.64M 26.06M 1.13B 7.15M 6.16M 5.78M 5.28M 9.92M 681M 9.99M 68.53M 26.66M 345M 26.86M 26.27M 1.14B
Logo Endonovo Therapeutics Inc
Endonovo Therapeutics, Inc. is a biotechnology company. The Company is focused on developing bioelectronic devices and cell therapies for regenerative medicine and is a commercial-stage developer of non-invasive wearable Electroceuticals therapeutic devices. The Company's portfolio of commercial and clinical-stage wearable Electroceuticals therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome, and multiple sclerosis. Its non-invasive Electroceutical therapeutic device, SofPulse, uses pulsed short-wave radiofrequency at approximately 27.12 megahertz (MHz) used for the palliative treatment of soft tissue injuries, and post-operative pain and edema, as well as for the treatment of chronic wounds. It offers an alternative, non-opioid treatment through its Electroceuticals systems.
Employees
-